# Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

> **NCT03030105** · PHASE1 · COMPLETED · sponsor: **Tetra Discovery Partners** · enrollment: 38 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** BPN14770
- **DRUG:** BPN14770 placebo
- **DRUG:** Donepezil
- **DRUG:** Donepezil placebo
- **DRUG:** Scopolamine 0.6 MG/ML
- **DRUG:** Scopolamine placebo

## Key facts

- **NCT ID:** NCT03030105
- **Lead sponsor:** Tetra Discovery Partners
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2017-05
- **Final completion:** 2017-06
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03030105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03030105, "Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03030105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*